Clinical Trial

Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

Study acronym: JAKUVEITE
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of the study is to evaluate the efficacy of Baricitinib, a JAK1 and 2 inhibitor, in the management of non-infectious non-anterior uveitis refractory to at least one line of biotherapy (anti-TNF alpha, tocilizumab) after 6 months of treatment
Protocol Amendment History 2 changes
notable Primary completion pushed: 2029-08 -> 2029-12 2026-06-09
minor Completion pushed: 2029-08 -> 2029-12 2026-06-09
Trial Details
NCT Number NCT05651880
Lead Sponsor University Hospital, Rouen
Conditions Active Non-anterior Non-infectious Uveitis
Enrollment 33 participants
Start Date 2026-07
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-08